Advertisement

Abdominal Radiology

, Volume 44, Issue 12, pp 4002–4003 | Cite as

Report from the pancreatic ductal adenocarcinoma disease focused panel

SAR DFP Report
  • 114 Downloads

Listing of all panel members

Avinash Kambadakone (Co-Chair)

Eric Tamm (Co-Chair)

Members

Hina Arif

Priya Bhosale

Olga Brook

Richard Do

Jason Fleming

Ajit Goenka

Alexander Guimaraes

Elizabeth Hecht

David Hough

Naveen Kulkarni

Ott Le

Lorenzo Mannelli

Michael Rosenthal

Guillermo Sangster

Zarine Shah

Erik Soloff

Parag Tolat

Zhen Jane Wang

Atif Zaheer

Marc Zins

Look back (most significant science/advances in field in past year)

The following are some of the more major advances in pancreatic cancer in 2018–2019.

Increasingly widespread use of testing for germline genetic changes, such as BRCA2. Patients with BRCA2 have a higher risk for developing cancers of the pancreas, prostate, breast, and ovaries, but are also notably more responsive to drugs such as PARP inhibitors and platinum-based therapies. Patients with a combination of mismatch repair deficiencies and microsatellite instability-high may respond to pembrolizumab. Current NCCN guidelines now recommend routine genetic testing for...

Notes

References

  1. 1.
    Tempero MA (2019) NCCN Guidelines Updates: Pancreatic Cancer. 17: 603Google Scholar
  2. 2.
    National Cancer Institute (2019) Advances in Pancreatic Cancer Research. retrieved: 09/06/2019; Available from: https://www.cancer.gov/types/pancreatic/research.
  3. 3.
    O’Hara MH, O’Reilly EM, Rosemarie M, et al (2019) Abstract CT004: A Phase Ib study of CD40 agonistic monoclonal antibody APX005M together with gemcitabine (Gem) and nab-paclitaxel (NP) with or without nivolumab (Nivo) in untreated metastatic ductal pancreatic adenocarcinoma (PDAC) patients. Cancer Research 79: CT004-CT004Google Scholar
  4. 4.
    National Comprehensive Cancer Network (2019) Pancreatic Adenocarcinoma (Version 3.2019). retrieved: 09/06/2019; Available from: https://www.nccn.org/professionals/physician_gls/pdf/pancreatic.pdf.
  5. 5.
    Murphy JE, Wo JY, Ryan DP, et al (2019) Total Neoadjuvant Therapy With FOLFIRINOX in Combination With Losartan Followed by Chemoradiotherapy for Locally Advanced Pancreatic Cancer: A Phase 2 Clinical Trial. JAMA Oncol 5: 1020-1027CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Personalised recommendations